Skip to main content
SpringerLink
Log in

Hypertrophic Cardiomyopathy

  • Chapter
  • First Online:
Clinical Cardiogenetics

Abstract

Hypertrophic cardiomyopathy (HCM) has been described in medical literature for several centuries. The resurgence of anatomy in the Renaissance allowed further study of the disease, and dissections of victims of sudden death revealed bulky hearts. 1 Nowadays, HCM is still a major cause of sudden cardiac death (SCD) in the young, and the most common monogenetic heart disease. 2–4 This chapter discusses not only the epidemiology, diagnosis, pathophysiology, and therapy of HCM but also deals with topics specific for cardiogenetic diseases like the genetic background, risk stratification for SCD, and the screening strategies in HCM families. It is intended to be of help for all involved in the care for HCM patients and their families.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Coats CJ, Hollman A. Hypertrophic cardiomyopathy: lessons from history. Heart. 2008;94:1258-1263.

    Article  PubMed  CAS  Google Scholar 

  2. Basso C, Calabrese F, Corrado D, Thiene G. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovasc Res. 2001;50:290-300.

    Article  PubMed  CAS  Google Scholar 

  3. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991;68:1388-1392.

    Article  PubMed  CAS  Google Scholar 

  4. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064-1075.

    Article  PubMed  CAS  Google Scholar 

  5. Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59:183-184.

    Article  PubMed  CAS  Google Scholar 

  6. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994;73:577-580.

    Article  PubMed  CAS  Google Scholar 

  7. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.

    Article  PubMed  CAS  Google Scholar 

  8. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation. 2006;113:2697-2705.

    Article  PubMed  Google Scholar 

  9. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116:14-18.

    Article  PubMed  Google Scholar 

  10. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699-1708.

    Article  PubMed  CAS  Google Scholar 

  11. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614.

    Article  PubMed  CAS  Google Scholar 

  12. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28:1-83.

    Article  PubMed  CAS  Google Scholar 

  13. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.

    Article  PubMed  Google Scholar 

  14. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.

    Article  PubMed  Google Scholar 

  15. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130-132.

    PubMed  CAS  Google Scholar 

  16. Central Bureau of Statistics. October. 2008. Ref Type: Generic

    Google Scholar 

  17. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-8.

    Article  PubMed  CAS  Google Scholar 

  18. Chevers N. Observations on the diseases of the orifice and valves of the aorta. Guys Hosp Rep. 1842;7:387-442.

    Google Scholar 

  19. Vulpian A. Contribution à l’étude des rétrécissements de l’orifice ventriculo-aortique. Arch Physiol. 1868;3:456-457.

    Google Scholar 

  20. Maron BJ, Wolfson JK, Roberts WC. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:785-790.

    Article  PubMed  CAS  Google Scholar 

  21. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-279.

    Article  PubMed  CAS  Google Scholar 

  22. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545-557.

    Article  PubMed  CAS  Google Scholar 

  23. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 2005;6:185-216.

    Article  PubMed  CAS  Google Scholar 

  24. Tsoutsman T, Lam L, Semsarian C. Genes, calcium and modifying factors in hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol. 2006;33:139-145.

    Article  PubMed  CAS  Google Scholar 

  25. Kubo T, Kitaoka H, Okawa M, et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005;46:1737-1743.

    Article  PubMed  CAS  Google Scholar 

  26. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.

    Article  PubMed  Google Scholar 

  27. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-424.

    Article  PubMed  CAS  Google Scholar 

  28. Maron BJ, Piccininno M, Casey SA, Bernabo P, Spirito P. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol. 2003;91:626-628.

    Article  PubMed  Google Scholar 

  29. Maron BJ, Casey SA, Hurrell DG, Aeppli DM. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy. Am J Cardiol. 2003;91:1195-1198.

    Article  PubMed  Google Scholar 

  30. Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46:1543-1550.

    Article  PubMed  Google Scholar 

  31. Binder J, Ommen SR, Gersh BJ, et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc. 2006;81:459-467.

    Article  PubMed  Google Scholar 

  32. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003;92:1183-1186.

    Article  PubMed  Google Scholar 

  33. Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J. 1976;17:611-629.

    Article  PubMed  CAS  Google Scholar 

  34. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.

    Article  PubMed  Google Scholar 

  35. Sanderson JE, Gibson DG, Brown DJ, Goodwin JF. Left ventricular filling in hypertrophic cardiomyopathy. An angiographic study. Br Heart J. 1977;39:661-670.

    Article  PubMed  CAS  Google Scholar 

  36. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005;45:1076-1080.

    Article  PubMed  Google Scholar 

  37. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27:1933-1941.

    Article  PubMed  Google Scholar 

  38. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.

    Article  PubMed  Google Scholar 

  39. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044-2051.

    Article  PubMed  CAS  Google Scholar 

  40. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-2524.

    Article  PubMed  CAS  Google Scholar 

  41. Charron P, Komajda M. Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. Expert Rev Mol Diagn. 2006;6:65-78.

    Article  PubMed  CAS  Google Scholar 

  42. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003;42:882-888.

    Article  PubMed  Google Scholar 

  43. Charron P, Carrier L, Dubourg O, et al. Penetrance of familial hypertrophic cardiomyopathy. Genet Couns. 1997;8:107-114.

    PubMed  CAS  Google Scholar 

  44. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 2001;38:315-321.

    Article  PubMed  CAS  Google Scholar 

  45. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248-1257.

    Article  PubMed  CAS  Google Scholar 

  46. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80:463-469.

    Article  PubMed  Google Scholar 

  47. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975;52:88-102.

    Article  PubMed  CAS  Google Scholar 

  48. Brown ML, Schaff HV. Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard. Expert Rev Cardiovasc Ther. 2008;6:715-722.

    Article  PubMed  Google Scholar 

  49. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83:326-331.

    Article  PubMed  CAS  Google Scholar 

  50. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131-139.

    Article  PubMed  Google Scholar 

  51. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J. 2001;22:1374-1450.

    Article  PubMed  CAS  Google Scholar 

  52. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-2218.

    Article  PubMed  CAS  Google Scholar 

  53. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774-778.

    Article  PubMed  CAS  Google Scholar 

  54. McKenna W, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47:532-538.

    Article  PubMed  CAS  Google Scholar 

  55. Swan DA, Bell B, Oakley CM, Goodwin J. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J. 1971;33:671-685.

    Article  PubMed  CAS  Google Scholar 

  56. Koga Y, Itaya K, Toshima H. Prognosis in hypertrophic cardiomyopathy. Am Heart J. 1984;108:351-359.

    Article  PubMed  CAS  Google Scholar 

  57. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol. 1993;72:970-972.

    Article  PubMed  CAS  Google Scholar 

  58. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;22:1374-1450.

    Google Scholar 

  59. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart. 1998;79:331-336.

    PubMed  CAS  Google Scholar 

  60. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:697-704.

    Article  PubMed  Google Scholar 

  61. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281:650-655.

    Article  PubMed  CAS  Google Scholar 

  62. Kofflard MJ, Waldstein DJ, Vos J, Ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol. 1993;72:939-943.

    Article  PubMed  CAS  Google Scholar 

  63. Cannan CR, Reeder GS, Bailey KR, Melton LJI, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation. 1995;92:2488-2495.

    Article  PubMed  CAS  Google Scholar 

  64. Kyriakidis M, Triposkiadis F, Anastasakis A, et al. Hypertrophic cardiomyopathy in Greece: clinical course and outcome. Chest. 1998;114:1091-1096.

    Article  PubMed  CAS  Google Scholar 

  65. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858-864.

    Article  PubMed  CAS  Google Scholar 

  66. Leonardi S, Raineri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30(16):2003-2010.

    Article  PubMed  Google Scholar 

  67. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.

    Article  PubMed  Google Scholar 

  68. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-1374.

    Article  PubMed  Google Scholar 

  69. Epstein AE, Dimarco JP, Ellenbogen KA, et al. Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008;117:e350-e408.

    Article  PubMed  Google Scholar 

  70. Zipes DP, Camm AJ, Borggrefe M, et al. Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-e484.

    Article  PubMed  Google Scholar 

  71. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373.

    Article  PubMed  CAS  Google Scholar 

  72. Maron BJ, Spirito P, Shen WK, et al. Implantable Cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-412.

    Article  PubMed  CAS  Google Scholar 

  73. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042-2048.

    Article  PubMed  CAS  Google Scholar 

  74. Girolami F, Olivotto I, Passerini I, et al. A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006;7:601-607.

    Article  Google Scholar 

  75. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59.

    Article  PubMed  CAS  Google Scholar 

  76. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:1903-1910.

    Article  PubMed  CAS  Google Scholar 

  77. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80:739-744.

    PubMed  Google Scholar 

  78. Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64:339-349.

    Article  PubMed  CAS  Google Scholar 

  79. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227-2232.

    Article  PubMed  Google Scholar 

  80. Bonne G, Carrier L, Bercovici J, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:438-440.

    Article  PubMed  CAS  Google Scholar 

  81. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006.

    Article  PubMed  CAS  Google Scholar 

  82. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:434-437.

    Article  PubMed  CAS  Google Scholar 

  83. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the Genes for Cardiac Troponin T and {alpha}-Tropomyosin in Hypertrophic Cardiomyopathy. N Engl J Med. 1995;332:1058-1065.

    Article  PubMed  CAS  Google Scholar 

  84. Posch MG, Thiemann L, Tomasov P, et al. Sequence analysis of myozenin 2 in 438 European patients with familial hypertrophic cardiomyopathy. Med Sci Monit. 2008;14:CR372-CR374.

    PubMed  CAS  Google Scholar 

  85. Osio A, Tan L, Chen SN, et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res. 2007;100:766-768.

    Article  PubMed  CAS  Google Scholar 

  86. Vasile VC, Will ML, Ommen SR, Edwards WD, Olson TM, Ackerman MJ. Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathy. Mol Genet Metab. 2006;87:169-174.

    Article  PubMed  CAS  Google Scholar 

  87. Theis JL, Bos JM, Bartleson VB, et al. Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2006;351:896-902.

    Article  PubMed  CAS  Google Scholar 

  88. Bos JM, Poley RN, Ny M, et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab. 2006;88:78-85.

    Article  PubMed  CAS  Google Scholar 

  89. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:2192-2201.

    Article  PubMed  CAS  Google Scholar 

  90. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman CE. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation. 2000;102:1950-1955.

    Article  PubMed  CAS  Google Scholar 

  91. Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, et al. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene. J Med Genet. 2006;43:829-832.

    Article  PubMed  CAS  Google Scholar 

  92. Richard P, Isnard R, Carrier L, et al. Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J Med Genet. 1999;36:542-545.

    PubMed  CAS  Google Scholar 

  93. Richard P, Charron P, Leclercq C, et al. Homozygotes for a R869G mutation in the beta -myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000;32:1575-1583.

    Article  PubMed  CAS  Google Scholar 

  94. Carrier L, Bonne G, Bahrend E, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res. 1997;80:427-434.

    PubMed  CAS  Google Scholar 

  95. Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol. 2006;48:A79-A89.

    Article  CAS  Google Scholar 

  96. Marian AJ, Mares A Jr, Kelly DP, et al. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. Eur Heart J. 1995;16:368-376.

    PubMed  CAS  Google Scholar 

  97. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280-285.

    Article  PubMed  CAS  Google Scholar 

  98. Hwang TH, Lee WH, Kimura A, et al. Early expression of a malignant phenotype of familial hypertrophic cardiomyopathy associated with a Gly716Arg myosin heavy chain mutation in a Korean family. Am J Cardiol. 1998;82:1509-1513.

    Article  PubMed  CAS  Google Scholar 

  99. Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol. 1998;9:88-99.

    Article  PubMed  CAS  Google Scholar 

  100. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114.

    Article  PubMed  CAS  Google Scholar 

  101. Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part II. Circulation. 2001;104:2249-2252.

    Article  PubMed  CAS  Google Scholar 

  102. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation. 1994;89:22-32.

    Article  PubMed  CAS  Google Scholar 

  103. Consevage MW, Salada GC, Baylen BG, Ladda RL, Rogan PK. A new missense mutation, Arg719Gln, in the beta-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathy. Hum Mol Genet. 1994;3:1025-1026.

    Article  PubMed  CAS  Google Scholar 

  104. Coviello DA, Maron BJ, Spirito P, et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a “hot spot” in the alpha-tropomyosin gene. J Am Coll Cardiol. 1997;29:635-640.

    Article  PubMed  CAS  Google Scholar 

  105. Havndrup O, Bundgaard H, Andersen PS, et al. The Val606Met mutation in the cardiac beta-myosin heavy chain gene in patients with familial hypertrophic cardiomyopathy is associated with a high risk of sudden death at young age. Am J Cardiol. 2001;87:1315-1317.

    Article  PubMed  CAS  Google Scholar 

  106. Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation. 1992;86:345-352.

    Article  PubMed  CAS  Google Scholar 

  107. Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of “benign” mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002;106:3085-3090.

    Article  PubMed  CAS  Google Scholar 

  108. Deinum J, van Gool JM, Kofflard MJ, Ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension. 2001;38:1278-1281.

    Article  PubMed  CAS  Google Scholar 

  109. Osterop AP, Kofflard MJ, Sandkuijl LA, et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension. 1998;32:825-830.

    Article  PubMed  CAS  Google Scholar 

  110. Friedrich FW, Bausero P, Sun Y, et al. A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J. 2009;30(13):1648-1655.

    Article  PubMed  CAS  Google Scholar 

  111. Monserrat L, Gimeno-Blanes JR, Marin F, et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2007;50:2399-2403.

    Article  PubMed  Google Scholar 

  112. Gollob MH, Green MS, Tang AS, Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol. 2002;17:229-234.

    Article  PubMed  Google Scholar 

  113. Rai TS, Ahmad S, Bahl A, et al. Genotype phenotype correlations of cardiac beta-myosin heavy chain mutations in Indian patients with hypertrophic and dilated cardiomyopathy. Mol Cell Biochem. 2009;321:189-196.

    Article  PubMed  CAS  Google Scholar 

  114. Forissier JF, Richard P, Briault S, et al. First description of germline mosaicism in familial hypertrophic cardiomyopathy. J Med Genet. 2000;37:132-134.

    Article  PubMed  CAS  Google Scholar 

  115. Watkins H, Thierfelder L, Hwang DS, McKenna W, Seidman JG, Seidman CE. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest. 1992;90:1666-1671.

    Article  PubMed  CAS  Google Scholar 

  116. Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. Circulation. 1995;91:2302-2305.

    Article  PubMed  CAS  Google Scholar 

  117. Cuda G, Perrotti N, Perticone F, Mattioli PL. A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy. Heart. 1996;76:451-452.

    Article  PubMed  CAS  Google Scholar 

  118. Alders M, Jongbloed R, Deelen W, et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848-1853.

    Article  PubMed  CAS  Google Scholar 

  119. Michels M, Solima OII, Kofflard MJ, et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in dutch myosin-binding protein c founder mutations. J Am Coll Cardiol Img. 2009;2:58-64.

    Article  Google Scholar 

  120. Moolman-Smook JC, De Lange WJ, Bruwer EC, Brink PA, Corfield VA. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am J Hum Genet. 1999;65:1308-1320.

    Article  PubMed  CAS  Google Scholar 

  121. Jaaskelainen P, Miettinen R, Karkkainen P, Toivonen L, Laakso M, Kuusisto J. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med. 2004;36:23-32.

    Article  PubMed  CAS  Google Scholar 

  122. Zahka K, Kalidas K, Simpson MA, et al. Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. Heart. 2008;94:1326-1330.

    Article  PubMed  CAS  Google Scholar 

  123. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol. 2007;8:113-126.

    Article  PubMed  CAS  Google Scholar 

  124. Mearini G, Schlossarek S, Willis MS, Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta. 2008;1782:749-763.

    Article  PubMed  CAS  Google Scholar 

  125. Chan PA, Duraisamy S, Miller PJ, et al. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat. 2007;28:683-693.

    Article  PubMed  CAS  Google Scholar 

  126. Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat. 2008;29:1265-1272.

    Article  PubMed  Google Scholar 

  127. Ortlepp JR, Vosberg HP, Reith S, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87:270-275.

    Article  PubMed  CAS  Google Scholar 

  128. Perkins MJ, Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J. 2005;26:2457-2462.

    Article  PubMed  CAS  Google Scholar 

  129. van Langen I, Hofman N, Tan HL, Wilde AA. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med. 2004;36(Suppl 1):116-124.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands

    Imke Christiaans

  2. Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands

    Imke Christiaans

Authors
  1. Imke Christiaans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucie Carrier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Imke Christiaans .

Editor information

Editors and Affiliations

  1. University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, 3508 GA, Netherlands

    H.F. Baars

  2. University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, 3508 GA, Netherlands

    P.A.F.M. Doevendans

  3. University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, 3508 GA, Netherlands

    J.J. van der Smagt

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Christiaans, I., Carrier, L. (2011). Hypertrophic Cardiomyopathy. In: Baars, H., Doevendans, P., van der Smagt, J. (eds) Clinical Cardiogenetics. Springer, London. https://doi.org/10.1007/978-1-84996-471-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-84996-471-5_3

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-470-8

  • Online ISBN: 978-1-84996-471-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation